ABCL-166: Tisagenlecleucel and lisocabtagene maraleucel: comparative efficacy in patients with relapsed/refractory diffuse large B-cell lymphoma

Among patients with relapsed/refractory DLBCL, there are no significant survival outcomes between CAR T-cell therapies tisagenlecleucel (tisa-cel) and lisocabtagene maraleucel (liso-cel), according to comparative analysis data presented during the 2021 Annual Meeting of the Society of Hematologic Oncology. Using data from the JULIET and TRANSCEND NHL 001 trials, the study showed comparable overall survival (HR: 1.12; 95% CI: 0.62–2.05, P = .71), progression-free survival (HR: 1.16; 95% CI: 0.64–2.09; P = .63), and complete response rate differences (–5.4%; 95% CI: –15.5%–4.7%; P = .29) between the tisa-cel and liso-cel cohorts.